Skip to content

Anxiety: all studies

Page 263 of 772: studies 2,621 to 2,630 of 7,715, newest first. Back to the anxiety overview

Research

Ayahuasca’s Antidepressant Effects Covary with Behavioral Activation as Well as Mindfulness

Journal of Psychoactive Drugs September 30, 2019 Maha N. Mian, Brianna R. Altman, Mitch Earleywine 47 citations

Ayahuasca, a plant-based hallucinogen that serves as a spiritual medicine in South America, has improved depression in at least one placebo-controlled clinical trial. Case studies suggest that dramatic behavioral changes often follow the Ayahuasca ceremony, but most explanations of antidepressant effects focus on changes in mindfulness. This study investigated whether both mindfulness and...

Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Swiss Medical Weekly September 30, 2019 Felix Mller, Stefan Borgwardt 10 citations

Lysergic acid diethylamide (LSD) is a potent hallucinogenic substance that was extensively investigated by psychiatrists during the 1950s and 1960s. Researchers were interested in the unique effects induced by this substance, some of which resemble symptoms seen in schizophrenia. Moreover, during that period LSD was studied and used for the treatment of several mental disorders such as...

The psychedelic renaissance: the next trip for psychiatry?

Irish Journal of Psychological Medicine September 23, 2019 John R. Kelly, Annie Baker, Mona Babiker et al. 22 citations

The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological...

Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers

Frontiers in Psychiatry September 13, 2019 Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder et al. 78 citations

Background: There is a growing interest in the use of psychedelic substances for health related purposes, including symptom relief for disorders like anxiety, depression, and pain. Although the focus of recent clinical trials has been on high doses of these substances, anecdotal evidence suggests that low (micro) doses are also effective, and may be more suitable for certain conditions....

DOI: 10.3389/fpsyt.2019.00672 (opens in new tab) Anxiety Mental health Depression economics Clinical psychology

Psilocybin for depression: Considerations for clinical trial design

Journal of Psychedelic Studies September 1, 2019 Kelley C. O’donnell, Sarah E. Mennenga, Michael P. Bogenschutz 15 citations

Background and aims Given the enormous global burden of depressive illness, there is an urgent need to develop novel and more effective treatments for major depressive disorder (MDD). Recent findings have suggested that psychedelic drugs may have a role in the treatment of depressive symptoms, and a number of groups are in the process of developing protocols to study this question...

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology September 1, 2019 Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al. 364 citations Retracted

Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Six randomized, double-blind, controlled clinical trials at five study sites were conducted...

DOI: 10.1007/s00213-019-05249-5 (opens in new tab) Full text (opens in new tab) MDMA-Assisted Psychotherapy Posttraumatic stress disorder MDMA Alongside Therapy Active MDMA +7

Opportunities in Novel Psychotropic Drug Design from Natural Compounds

The International Journal of Neuropsychopharmacology July 26, 2019 Siu Wa Tang, Wayne H. Tang 19 citations

Multiple initiatives at the national and international level support natural drug discovery. Psychiatrists and patients are not well informed about natural psychotropics in general. Existing antidepressant and antipsychotic drugs were developed from atropine, a natural product. Subsequent drug developments were largely based on extension and modification of earlier molecular scaffolds. This...

DOI: 10.1093/ijnp/pyz042 (opens in new tab) Full text (opens in new tab) Anxiety Natural product Psychotropic drug Antidepressant +5

Mindfulness‐based stress reduction for psychological distress among nurses: A systematic review

Journal of Clinical Nursing July 3, 2019 Sajed Faisal Ghawadra, Khatijah Lim Abdullah, Wan Yuen Choo et al. 163 citations

AIMS AND OBJECTIVES: To explore the studies that used interventions based on the Mindfulness-Based Stress Reduction (MBSR) for decreasing psychological distress among nurses. BACKGROUND: Because of the demanding nature of their work, nurses often have significantly high levels of stress, anxiety and depression. MBSR has been reported to be an effective intervention to decrease psychological...

DOI: 10.1111/jocn.14987 (opens in new tab) Anxiety Mindfulness-based stress reduction Psychological intervention Burnout +6

Link between personality and response to THC exposure

bioRxiv (Cold Spring Harbor Laboratory) June 17, 2019 Tetiana Kardash, Dmitry Rodin, Michael Kirby et al. preprint

ABSTRACT The effects of cannabis reported by users range from experiences of euphoria and anxiolytic effects to paranoia, anxiety, and increased risk of depression. Attempts to reconcile the apparent contradictions in user response have not been conclusive. Here, we utilized selectively-bred stress-resilient socially dominant (Dom) and stress-sensitive socially submissive (Sub) mice to...

Faces of HPPD: Hallucinogen Persisting Perception Disorder Patient Survey Results and a Descriptive Analysis of Patient Demographics, Medical Background, Drug Use History, Symptoms, and Treatments

Addictive Disorders & Their Treatment June 10, 2019 Doreen M. Lewis 2 citations

Objective: The purpose of the present study was to obtain patient information across a wide geography about medical history, drug use, symptoms, and treatments of individuals diagnosed with hallucinogen persisting perception disorder (HPPD). Methods: The study was an internet survey that yielded 26 HPPD patients from North America (81%), Europe (12%), and South America (almost 8%),...